Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-EU: Long-Term Safety and Outcomes of Livmarli in ALGS and PFIC
NCT07290257Phase 4Recruiting
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Sep 2025
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 4 trial of maralixibat in Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), sponsored by Mirum Pharmaceuticals, Inc.. Started Sep 2025; status: recruiting.
02
Drugs
maralixibat
03
Conditions
Alagille syndrome (ALGS)progressive familial intrahepatic cholestasis (PFIC)
Beyond the preview
Go deeper on NCT07290257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07290257.